Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.
This review provides a broad educational overview of pharmacological agents used in diabetes management, spanning both traditional and newer-generation therapies, with particular attention to their off-label use for weight loss. The authors describe the mechanistic and clinical distinctions between type 1 and type 2 diabetes and survey established drug classes—insulin, metformin, sulfonylureas, and thiazolidinediones—noting their limitations such as hypoglycemia risk and weight gain. The review then highlights the clinical impact of incretin-based therapies, specifically GLP-1 receptor agonists and SGLT-2 inhibitors, which the authors associate with improved glycemic control, weight reduction, and cardiorenal benefits. Newer dual and triple agonists, including tirzepatide, are described as producing HbA1c and body weight reductions approaching those of bariatric surgery. The paper raises concerns about the rising off-label use of antidiabetic agents for weight management, citing gastrointestinal adverse effects and rare motility disorders. Limitations include the review's broad scope and lack of original data or formal systematic methodology. The authors call for ongoing pharmacovigilance, equitable access, and further research into long-term safety and emerging oral non-peptide incretin mimetics.
Why this grade: This is a narrative review synthesizing existing literature without original data collection, randomization, or formal systematic methodology, placing it in the review evidence category.
Objective: Diabetes mellitus encompasses chronic metabolic disorders marked by impaired insulin secretion, action, or both, with type 1 and type 2 diabetes presenting distinct mechanisms and therapeutic needs. Achieving durable glycemic control remains essential to preventing microvascular and macrovascular complications. Data Sources: The growing prevalence of obesity among people with diabetes-driven by insulin resistance, lifestyle factors, and, in type 1 diabetes, insulin-associated weight gain-has increased the demand for therapies targeting both glycemia and body weight. Study Selection and Data Extraction: Traditional agents such as insulin, metformin, sulfonylureas, and thiazolidinediones have long served as treatment foundations but are limited by risks like hypoglycemia and weight gain. Incretin-based therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors, have reshaped diabetes care by improving glycemic control, promoting weight loss, and offering cardiovascular and renal protection. Data Synthesis: Newer dual and multiagonists, including tirzepatide and emerging triple agonists, show unprecedented reductions in HbA 1c and body weight, approaching outcomes seen with bariatric surgery. However, rising off-label use of antidiabetic drugs for weight loss raises safety concerns, including gastrointestinal effects and rare motility disorders, underscoring the need for careful patient selection and pharmacovigilance. Conclusion: Ongoing challenges include high costs, inequities in access, medication shortages, and the need for sustained pharmacovigilance. Future directions involve oral non-peptide incretin mimetics, broader indications for multiagonists, and deeper understanding of long-term safety, particularly in off-label contexts.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.